Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Acadia Pharmaceuticals (ACAD) PT Lowered to $26 at Needham & Company
August 5, 2021 6:30 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $30.00) while maintaining a Buy rating.
The analyst commented, "ACAD reported $115.2M in 2Q21 Nuplazid sales, below our $130.0M and consensus $126.3M ests. Sales +vely impacted by volume... More
Acadia Pharma (ACAD) Q2 Revs of $115.2M; Tops EPS by 4c
August 4, 2021 4:19 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.27), $0.04 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $115.2 million versus the consensus estimate of $126.15 million.
GUIDANCE:
Acadia Pharma sees Q3 2021 revenue of $480-515 million, versus the consensus of... More
